Botulinum toxin treatment in patients with facial synkinesis.

doi:10.1007/978-3-642-85090-5_70

Paper

Botulinum toxin treatment in patients with facial synkinesis.

Published Dec 1, 1994 · R. Laskawi, W. Damenz, P. Roggenkämper

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Q1 SJR score

22

Citations

0

Influential Citations

Full text

Semantic Scholar

Abstract

Botulinum toxin therapy (BTT), originally applied to treat strabism (for review see [8]), is now established as a minimally invasive, successful therapy in a number of diseases. The treatment of mass movements (synkinesis) following paralysis of the facial nerve, which may have various etiologies, has recently been reported as another indication. First experiences with BTT, applied to several patients with such synkinesis, were published by Roggenkamper et al. [7]. This indication was also confirmed by case reports by other authors [2, 6]. According to Roggenkamper et al. [7] this treatment is effective for an average of 11 weeks after the first injection, according to patients’ personal assessment.

Study Snapshot

Key takeawayBotulinum toxin therapy (BTT) effectively treats facial synkinesis in patients with paralysis of the facial nerve, providing a minimally invasive treatment option for mass movements.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Botulinum toxin treatment in patients with facial synkinesis.

References

Citations